Together, these drugs have transformed how medicine approaches obesity, diabetes and a growing list of other conditions
Quick Comparison Clinical Trial Results: What the Data Actually Shows Retatrutide TRIUMPH Phase 3 Program Retatrutide has completed two Phase 3 trials in obesity populations, both showing nearly identical results despite different patient populations and durations which is exactly what a robust efficacy signal looks like
Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY
Moreover, dual GLP-1 and Gcg receptor agonist, dual GLP-1/GIP receptor agonist and GLP-1/GIP/Gcg receptor triagonist have also been successfully applied in the treatment of AD models
The field is so far proving to be unpredictable
Across the retatrutide trials so far, rates have ranged from 2 to 11% in active groups (depending on dose) versus 2% on placebo